Can linvoseltamab improve outcomes for patients with relapsed/refractory multiple myeloma compared to standard care?
Linvoseltamab is a bispecific antibody that targets BCMA, a protein on myeloma cells. For patients with relapsed/refractory multiple myeloma (RRMM) who have tried several treatments, linvoseltamab offers a new option. A 2025 study compared linvoseltamab to teclistamab, another BCMA bispecific antibody, and found linvoseltamab may lead to better outcomes, including longer survival and higher response rates.
What the research says
A 2025 indirect comparison study used patient data from the LINKER-MM1 trial (linvoseltamab) and the MajesTEC-1 trial (teclistamab) to compare the two drugs in triple-class exposed RRMM patients 9. After matching patients on key factors, linvoseltamab showed significantly longer progression-free survival (PFS) and overall survival (OS) compared to teclistamab 9. Linvoseltamab also had numerically higher rates of overall response, very good partial response or better, complete response, and minimal residual disease negativity 9. These results suggest linvoseltamab may be more effective than teclistamab, though direct head-to-head trials are needed. Bispecific antibodies like linvoseltamab are considered highly effective for RRMM, but they can cause side effects such as cytokine release syndrome (CRS) and infections 58. In teclistamab studies, infections occurred in over half of patients, with grade 3 or higher infections in about 28% 5. Managing these side effects is important for safe treatment.
What to ask your doctor
- Is linvoseltamab an option for my relapsed/refractory multiple myeloma, given my treatment history?
- How does linvoseltamab compare to other BCMA-targeted therapies like teclistamab in terms of effectiveness and side effects?
- What are the common side effects of linvoseltamab, especially infections and CRS, and how are they managed?
- What monitoring or supportive care would I need during linvoseltamab treatment?
- Are there any ongoing clinical trials for linvoseltamab that I might be eligible for?
This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.